LFA-1 regulated by IL-2/STAT5 pathway boosts antitumor function of intratumoral CD8+ T cells for improving anti-PD-1 antibody therapy

These findings indicate that LFA-1-midiated immune synapse acts as a regulator of the antitumor function of intratumoral CD8+ T cells, which can be applied to improve anti-PD-1 antibody therapy. Female C57BL/6J mice (aged 6–8 weeks) were purchased from SPF Biotechnology Co., Ltd. (Beijing, China).mice were subcutaneously implanted with 1×106 B16 cells into the right flank on day 0. CD8+ T cells in TILs from B16 tumor-bearing mice were sorted on day 7 and day 14 using mouse CD8a microbeads (Miltenyi Biotec, 130-117-044) according to the manufacturer’s protocol. In brief, single-cell suspensions from tumor tissues were incubated with mouse CD8a microbeads for 10 min at 4 ℃. After magnetic labeling, the CD8+ T cells were isolated using a column. RNA was isolated using a TRIzol reagent (Invitrogen, cat, #15596026CN). RNA-seq and data analyses were conducted by SeqHealth Technology Co., Ltd. (Wuhan, China).